Automated red blood cell exchange with a post‐procedure haematocrit targeted at 34% in the chronic management of sickle cell disease
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19674 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Jules M Ross und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hematology-Oncology Division, Departement of Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, Canada. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Erythrocyte Transfusion. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Optimal targets for red blood cell exchange (RCE) are not well defined in the chronic management of sickle cell disease. We analysed transfusion requirements and iron‐related outcomes in 101 patients on chronic RCE with a post‐procedure haematocrit (Ht) targeted at 34%, which is higher than typically used. A majority were of HbSS/HbSβ0 genotype ( n = 72) and enrolled for neurological complications ( n = 53). Fifty patients had a positive Ht balance with RCE (>2% mean increase from pre‐procedure level), while 43 patients maintained a neutral balance. The first group required fewer red blood cell units/year (65 vs. 80, p < 0.001), but a significant proportion were iron overloaded based on R2* with liver MRI (32% vs. none performed) and prescription of iron chelation (52% vs. 0%, p < 0.001, after a median of 19 months). The second group was more likely to receive iron supplementation (6% vs. 56%, p < 0.001). Chronic automated RCE with a post‐procedure Ht targeted at 34% is not iron‐neutral, and personalized Ht goals may be more appropriate in certain settings. This higher target should be compared with a lower Ht strategy in individuals with similar baseline red cell volumes to assess iron homeostasis and blood product requirements.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematology-Oncology Division, Departement of Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, Canada.
- Cardiology Division, Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, Canada.
ORCID-Profile: Jules M Ross
Zitieren
APA
M Ross, J., Forté, S., Mercure-Corriveau, N., Lemay, A. S., Rioux-Massé, B., Potter, B. J., & Soulières, D. (2024). Automated red blood cell exchange with a post‐procedure haematocrit targeted at 34% in the chronic management of sickle cell disease. British Journal of Haematology. https://doi.org/10.1111/bjh.19674
Vancouver
M Ross J, Forté S, Mercure-Corriveau N, Lemay AS, Rioux-Massé B, Potter BJ, et al. Automated red blood cell exchange with a post‐procedure haematocrit targeted at 34% in the chronic management of sickle cell disease. British Journal of Haematology. 2024. doi:10.1111/bjh.19674
BibTeX
@article{MRoss2024,
author = {M Ross, Jules and Forté, Stéphanie and Mercure-Corriveau, Nicolas and Lemay, Anne-Sophie and Rioux-Massé, Benjamin and Potter, Brian J and Soulières, Denis},
title = {Automated red blood cell exchange with a post‐procedure haematocrit targeted at 34% in the chronic management of sickle cell disease},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19674}
}
EUVIMED